90 related articles for article (PubMed ID: 27060653)
1. Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid.
Moore C; Duvall E; Braby E; Reid G; Docherty E; Grieve L; Cubie H; Graham C; Cuschieri K
J Clin Virol; 2016 Jun; 79():32-35. PubMed ID: 27060653
[TBL] [Abstract][Full Text] [Related]
2. Effect of glacial acetic acid pre-treatment of cervical liquid-based cytology specimens on the molecular detection of human papillomavirus.
Moore C; Cuschieri K; McQueen F; Duvall E; Graham C; Cubie HA
Cytopathology; 2013 Oct; 24(5):314-20. PubMed ID: 23379748
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results.
Binnicker MJ; Pritt BS; Duresko BJ; Espy MJ; Grys TE; Zarka MA; Kerr SE; Henry MR
J Clin Microbiol; 2014 Oct; 52(10):3763-8. PubMed ID: 25122861
[TBL] [Abstract][Full Text] [Related]
4. Stability of human papillomavirus (HPV) in cervical ThinPrep specimens previously lysed with glacial acetic acid: effect on cobas 4800 HPV test performance.
McMenamin M; McKenna M
Cancer Cytopathol; 2014 Apr; 122(4):250-6. PubMed ID: 24302639
[TBL] [Abstract][Full Text] [Related]
5. Transition from Hybrid Capture 2 to Cobas 4800 in Hpv detection: sensitivity and specificity for Cin2+ in two time periods.
Bottari F; Boveri S; Iacobone AD; Gulmini C; Igidbashian S; Cassatella MC; Landoni F; Sandri MT
Infect Dis (Lond); 2018 Jul; 50(7):554-559. PubMed ID: 29463149
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
7. Precancerous cervical lesions and HPV genotypes identified in previously unsatisfactory cervical smear tests after inexpensive glacial acetic acid processing.
Risley C; Geisinger KR; Robinson JC; Stewart MW; Zhang L; Alexander R; Raab SS
Int J Gynaecol Obstet; 2019 Jan; 144(1):85-89. PubMed ID: 30362108
[TBL] [Abstract][Full Text] [Related]
8. Comparison of INNO-LiPA genotyping extra and hybrid capture 2 assays for detection of carcinogenic human papillomavirus genotypes.
Barzon L; Militello V; Pagni S; Palù G
J Clin Virol; 2012 Nov; 55(3):256-61. PubMed ID: 22877561
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of screening performance of HPV DNA test on specimens from different sites of the female genital tract].
Zhang S; Kang L; Liu B; Cui J; Chen F; Liu X; Wang H; Chen W
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):389-93. PubMed ID: 25030599
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
14. Effect of glacial acetic acid treatment of liquid-based cytology collections on performance of Cervista HPV HR for detection of high-risk human papillomavirus.
Munson E; Du Chateau BK; Nelson BE; Griep J; Czarnecka J; Amrhein RD; Schroeder ER
J Clin Microbiol; 2012 Jun; 50(6):2129-31. PubMed ID: 22442317
[TBL] [Abstract][Full Text] [Related]
15. Validation of ThermoFisher's Papspin for human papillomavirus detection in cervicovaginal specimens using PCR with GP5+/GP6+ primers and the Hybrid Capture II assay.
Weynand B; Delvenne P; Polet R; Guiot Y; Arafa M; Somja J; Galant C
Clin Microbiol Infect; 2010 Jun; 16(6):671-5. PubMed ID: 19689463
[TBL] [Abstract][Full Text] [Related]
16. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
[TBL] [Abstract][Full Text] [Related]
18. Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea.
Toliman PJ; Kaldor JM; Badman SG; Gabuzzi J; Silim S; Kumbia A; Kombuk B; Kombati Z; Munnull G; Guy R; Vallely LM; Kelly-Hanku A; Wand H; Ryan C; Tan G; Brotherton J; Saville M; Mola GDL; Garland SM; Tabrizi SN; Vallely AJ
Papillomavirus Res; 2018 Dec; 6():70-76. PubMed ID: 30391365
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection.
Halfon P; Benmoura D; Agostini A; Khiri H; Penaranda G; Martineau A; Blanc B
J Clin Virol; 2010 Aug; 48(4):246-50. PubMed ID: 20541966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
